Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+4.81M
-
Total reported value, excl. options
-
$188M
-
Value change
-
+$19.5M
-
Put/Call ratio
-
1.6
-
Number of buys
-
59
-
Number of sells
-
-58
-
Price
-
$3.78
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q4 2024
151 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q4 2024.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
of 111M outstanding shares and own 44.94% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (6.77M shares), TCG Crossover Management, LLC (4.64M shares), VANGUARD GROUP INC (2.69M shares), BANK OF AMERICA CORP /DE/ (2.43M shares), BlackRock, Inc. (2.28M shares), Almitas Capital LLC (2.03M shares), CITADEL ADVISORS LLC (1.97M shares), 683 Capital Management, LLC (1.93M shares), GOLDMAN SACHS GROUP INC (1.86M shares), and Boxer Capital Management, LLC (1.75M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.